The Hindu

Amgen cholesterol drug cuts risk of first cardiac event by 25%

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...
Reuters

Amgen cholesterol drug cuts risk of first cardiac event by 25%

Nov 8 (Reuters) - Adding Amgen's (AMGN.O), opens new tab cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack ...
Yahoo Finance

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
STAT

Amgen’s cholesterol shot prevented first heart attacks and strokes, more detailed data affirm

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A cholesterol-lowering injection ...
Pharmabiz

Amgen makes Repatha available through AmgenNow, a direct-to-patient programme in the US

Amgen announced the launch of AmgenNow, a new direct-to-patient programme starting with Repatha (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of ...
Pharm Exec

Amgen Launches New Direct-To-Patient Program AmgenNow

AmgenNow, a direct-to-patient program, launches with Repatha, following positive Phase III Vesalius-CV trial results showing reduced cardiovascular events. Starting October 6, 2025, AmgenNow will be ...
Seeking Alpha

Amgen to offer Repatha at 60% discount to U.S. consumers

Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...
Investing

Amgen makes Repatha available at nearly 60% discount via direct program

Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that regulates LDL cholesterol levels in the bloodstream. The medication is approved in more than 74 countries for reducing ...
Healio

Repatha made available via direct-to-patient program at discounted price

Please provide your email address to receive an email when new articles are posted on . Evolocumab will be made available to eligible patients via a new direct-to-consumer program. The PCSK9 inhibitor ...
PharmiWeb

GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings

The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the ...
MarketWatch

Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...